Study guide

19.1 Valvular Heart Disease, CAD & Cardiopulmonary Bypass Management

NBCRNA CRNA Certified Registered Nurse Anesthetist NCE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Cardiovascular, Respiratory & CNS Physiology & Pathophysiology

1.1 Cardiovascular Physiology, Hemodynamics & Ischemic Heart Disease 1.2 Respiratory Physiology, Lung Volumes & Chronic Pulmonary Pathophysiology 1.3 Central & Autonomic Nervous System Physiology & Neurological Disorders

2 Chapter 2: Hepatorenal, Endocrine & Hematologic/Immune Systems

2.1 Renal Physiology, Glomerular Filtration & Acid-Base Balance 2.2 Hepatic Physiology, Drug Clearance & Gastrointestinal Considerations 2.3 Endocrine Disorders, Hematology, Coagulation & Immune Mechanisms

3 Chapter 3: Anesthetic Pharmacology: Inhalation Agents, Intravenous Anesthetics & Sedatives

3.1 Inhalation Anesthetics: Uptake, Distribution, Blood/Gas Solubility & MAC 3.2 Intravenous Hypnotics: Propofol, Etomidate, Ketamine & Barbiturates 3.3 Opioid Agonists/Antagonists, Benzodiazepines & Reversal Pharmacology

4 Chapter 4: Anesthetic Pharmacology: Neuromuscular Blockers, Local Anesthetics & Physics

4.1 Neuromuscular Blocking Agents & Reversal: Anticholinesterases vs Sugammadex 4.2 Local Anesthetics: Mechanism, Potency, Toxicity (LAST) & Vasoconstrictors 4.3 Applied Physics, Gas Laws, Fluid Dynamics & Anesthesia Mathematics

5 Chapter 5: Anesthesia Delivery Systems & Gas Supplies

5.1 Medical Gas Supply Systems, Cylinders, Regulators & Safety Index Systems (PISS/DISS) 5.2 Anesthesia Machine High, Intermediate & Low Pressure Systems & Failsafe Mechanisms 5.3 Vaporizer Technology: Variable-Bypass vs Desflurane Vaporizers & Machine Checkout

6 Chapter 6: Breathing Circuits, CO2 Absorption & Ventilators

6.1 Breathing Circuits: Circle System, Mapleson Classifications & Dead Space 6.2 Carbon Dioxide Absorption: Soda Lime Chemistry, Desiccation, Carbon Monoxide & Compound A 6.3 Anesthesia Ventilators, Pressure/Volume Modes, APL Valves & Waste Gas Scavenging

7 Chapter 7: Airway Equipment & Advanced Airway Instrumentation

7.1 Face Masks, Supraglottic Airways (LMA Types) & Endotracheal Tubes 7.2 Direct Laryngoscopy (Mac/Miller) & Video Laryngoscopy 7.3 Fiberoptic Intubation, Bronchial Blockers, Double-Lumen Tubes & Surgical Airways

8 Chapter 8: Patient Monitoring, Hemodynamics & Electrosurgical Safety

8.1 Noninvasive Monitoring: Pulse Oximetry, Capnography Waveforms & Temperature 8.2 Invasive Hemodynamics: Arterial Lines, CVP & Pulmonary Artery Catheters 8.3 Neuromuscular Monitoring (TOF/PTC), Depth of Anesthesia (EEG/BIS) & Electrical Safety

9 Chapter 9: Preoperative Assessment, Risk Stratification & Preparation

9.1 Preoperative History, Physical Examination & ASA Physical Status Classification 9.2 Cardiac & Pulmonary Risk Stratification, Diagnostic Testing & Optimization 9.3 Preoperative Fasting Guidelines, Aspiration Prophylaxis & Premedication

10 Chapter 10: Fluid Management, Blood Component Therapy & Coagulation Monitoring

10.1 Crystalloids vs Colloids, Maintenance & Deficit Calculations 10.2 Blood Component Therapy, Transfusion Triggers & Massive Transfusion Protocols 10.3 Point-of-Care Coagulation: TEG, ROTEM & Perioperative Coagulopathies

11 Chapter 11: Airway Management Strategies & Difficult Airway Algorithms

11.1 Difficult Airway Assessment: Mallampati, Cormack-Lehane & Airway Predictors 11.2 ASA Difficult Airway Algorithm: Anticipated vs Unanticipated Difficult Airway 11.3 "Cannot Intubate, Cannot Oxygenate" (CICO) & Emergency Front-of-Neck Access (eFONA)

12 Chapter 12: General Anesthesia: Induction, Maintenance, Emergence & TIVA

12.1 Rapid Sequence Induction (RSI), Cricoid Pressure & Intubation Protocols 12.2 Balanced Anesthesia vs Total Intravenous Anesthesia (TIVA) Principles 12.3 Emergence, Extubation Criteria, Deep vs Awake Extubation & Laryngospasm

13 Chapter 13: Regional Anesthesia: Neuraxial Blocks

13.1 Spinal Anesthesia: Anatomy, Physiology, High Spinal & Complications 13.2 Epidural & Combined Spinal-Epidural (CSE) Techniques & PDPH 13.3 Neuraxial Anticoagulation Guidelines (ASRA) & Epidural Hematoma

14 Chapter 14: Regional Anesthesia: Peripheral Nerve Blocks & Ultrasound Guidance

14.1 Upper Extremity Peripheral Nerve Blocks: Interscalene, Supraclavicular, Axillary 14.2 Lower Extremity & Truncal Blocks: Femoral, Sciatic, TAP & ESP Blocks 14.3 Ultrasound Physics, Needle Visualization & LAST Rescue Protocols

15 Chapter 15: Perioperative Safety, Positioning, PACU, Ethics & Professional Practice

15.1 Surgical Positioning Complications: Nerve Injuries & Physiologic Changes 15.2 PACU Discharge Criteria, PONV Management, Hypoxemia & Emergence Delirium 15.3 Malignant Hyperthermia Protocol & Operating Room Crisis Management 15.4 CRNA Ethics, Informed Consent, Scope of Practice & Wellness Initiatives

16 Chapter 16: Obstetric & Gynecologic Anesthesia

16.1 Maternal Physiology & Pharmacokinetics Across Trimesters 16.2 Labor Analgesia & Anesthesia for Cesarean Delivery 16.3 Obstetric Emergencies: Preeclampsia, Hemorrhage & Amniotic Fluid Embolism 16.4 Nonobstetric Surgery in the Pregnant Patient

17 Chapter 17: Pediatric Anesthesia

17.1 Pediatric Anatomy, Physiology, Airway & Developmental Pharmacology 17.2 Pediatric Induction, Maintenance, Fluids & Emergence Agitation 17.3 Pediatric Respiratory Emergencies: Croup, Epiglottitis & Laryngospasm

18 Chapter 18: Geriatric, Bariatric & Ambulatory Anesthesia

18.1 Geriatric Physiology, Pharmacodynamics & Postoperative Delirium/POCD 18.2 Bariatric Anesthesia: Obesity Hypoventilation, OSA & Dosing Adjustments 18.3 Ambulatory Surgery Selection Criteria & ERAS Protocols

19 Chapter 19: Cardiac, Vascular & Thoracic Anesthesia

19.1 Valvular Heart Disease, CAD & Cardiopulmonary Bypass Management 19.2 Vascular Anesthesia: Carotid Endarterectomy & Aortic Cross-Clamping 19.3 Thoracic Anesthesia: One-Lung Ventilation & Hypoxic Pulmonary Vasoconstriction

20 Chapter 20: Neurosurgical, Intra-Abdominal, Extrathoracic, Head/Neck & Trauma Anesthesia

20.1 Neurosurgical Anesthesia: ICP Dynamics, Craniotomy & Venous Air Embolism 20.2 Intra-Abdominal, Laparoscopy & Endocrine Tumor Anesthesia (Pheochromocytoma, Carcinoid) 20.3 ENT/Shared Airway, Extrathoracic Procedures & Trauma/Burn Resuscitation

21 Chapter 21: Neurologic, Gastrointestinal & Substance-Related Pathophysiology and Pharmacology

21.1 Neurodegenerative & Demyelinating Disease and Antiparkinsonian Pharmacology 21.2 Gastrointestinal & Exocrine Pancreatic Disorders: Esophageal, Gastric, Pancreatitis & Malabsorption 21.3 Cannabinoids, Herbal Remedies & Dietary Supplements

22 Chapter 22: Imaging Safety, Patient Warming & Infusion Technology

22.1 Fluoroscopy, Radiography & Radiation Safety in Anesthetizing Locations 22.2 Patient Warming Equipment & Rapid Infusion Devices

23 Chapter 23: Pain Medicine: Theory, Chronic Pain & Interventional Procedures

23.1 Pain Theory: Nociception, Sensitization & Chronic Pain Pathophysiology 23.2 Chronic Pain Management, Medication-Assisted Therapy & the Opioid-Tolerant Patient 23.3 Interventional Pain Procedures & Anesthesia for Pain Management Cases

24 Chapter 24: Professional Practice: Research Ethics, Error Disclosure & Provider Infection Control

24.1 Research Ethics, IRB Oversight & Protection of Human Subjects 24.2 Disclosure of Errors and Injuries, Adverse Event Reporting & Just Culture 24.3 Provider Infection Control: PPE, Air Handling & Occupational Exposure

25 Chapter 25: Neurosurgical Subspecialty Procedures

25.1 Cerebral Aneurysm Clipping, AVM Resection & Subarachnoid Hemorrhage 25.2 Transsphenoidal Hypophysectomy & Pituitary Surgery 25.3 Stereotactic Procedures, Deep Brain Stimulation & Awake Craniotomy 25.4 CSF Diversion, Burr Holes, Ventriculoperitoneal Shunts & Decompressive Craniectomy

26 Chapter 26: Head, Neck, Nasal, Dental & Ophthalmic Anesthesia

26.1 Nasal & Sinus Surgery, Nasotracheal Intubation & Craniofacial Procedures 26.2 Dental, Orthodontic, Oral-Maxillofacial & Ophthalmic Anesthesia 26.3 Neck Tumors, Radical Neck Dissection, Lymph Node Biopsy & Thyroid/Parathyroid Surgery

27 Chapter 27: Orthopedic & Extremity Anesthesia

27.1 Total Joint Arthroplasty, Bone Cement Implantation Syndrome & Tourniquet Physiology 27.2 Closed Reduction, Hand and Foot Procedures & Intravenous Regional (Bier) Block

28 Chapter 28: Non-Operating-Room Anesthesia: Interventional, Imaging & Radiation Therapy

28.1 Interventional and Neurointerventional Radiology Anesthesia 28.2 Radiation Therapy, Diagnostic Imaging & MRI-Suite Anesthesia

29 Chapter 29: Special Populations: Substance Use Disorder, Immunocompromised & Oncology Patients

29.1 Acute Intoxication, Withdrawal Syndromes & Perioperative Complications 29.2 Anesthesia for the Immunocompromised & Oncology Patient

19.1 Valvular Heart Disease, CAD & Cardiopulmonary Bypass Management

Key Takeaways Explain This Topic AI

Aortic Stenosis (normal valve area 3.0-4.0 cm², severe < 1.0 cm², mean gradient > 40 mmHg) produces concentric LV hypertrophy with fixed outflow obstruction; hemodynamic management mandates maintaining normal sinus rhythm, slow-normal heart rate (60-70 bpm), high preload, and maintained SVR to preserve coronary perfusion pressure (CPP = DBP - LVEDP), while strictly avoiding tachycardia, hypovolemia, and hypotension.

Regurgitant lesions (Aortic Regurgitation and Mitral Regurgitation) follow the 'fast, forward, full' hemodynamic paradigm: elevated heart rates (80-100 bpm) shorten diastolic or systolic regurgitant time, while reduced afterload (low SVR) promotes forward cardiac output and minimizes retrograde volume.

Mitral Stenosis (normal valve area 4.0-5.0 cm², severe < 1.5 cm²) causes fixed left ventricular inflow obstruction and left atrial hypertension; management requires slow heart rates (60-70 bpm) to maximize diastolic filling time, preservation of sinus rhythm, and aggressive avoidance of pulmonary vasoconstrictors (hypoxia, hypercapnia, acidosis, nitrous oxide, alpha-1 agonists) that precipitate acute right ventricular failure.

Cardiopulmonary Bypass (CPB) anticoagulation requires systemic unfractionated heparin (300-400 U/kg) targeting an Activated Clotting Time (ACT) > 400-480 seconds prior to cannulation; heparin resistance secondary to Antithrombin III (ATIII) deficiency is treated with ATIII concentrate or Fresh Frozen Plasma (FFP, 2-4 units); high-potassium cold cardioplegia arrests the myocardium in electrical and mechanical diastole.

Heparin reversal is achieved with protamine sulfate (1.0-1.3 mg per 100 units of heparin); adverse protamine reactions include Type I (hypotension from rapid injection), Type II (anaphylactic/anaphylactoid reactions, highest in patients with prior NPH insulin, fish allergy, or post-vasectomy antisperm antibodies), and Type III (catastrophic pulmonary hypertension and RV collapse from thromboxane A2 release).

Last updated: August 2026

19.1 Valvular Heart Disease, CAD & Cardiopulmonary Bypass Management

Cardiac anesthesia for the Certified Registered Nurse Anesthetist (CRNA) demands mastery of valvular pathophysiology, coronary perfusion dynamics, and the non-physiologic state of cardiopulmonary bypass (CPB). Anesthesia providers must tailor inotropes, vasopressors, fluid administration, and ventilatory parameters to match specific pressure-volume relationships and preserve myocardial oxygen supply-demand balance.

1. Valvular Heart Disease Hemodynamics: The Master Framework

Valvular lesions are classified by their primary hemodynamic insult: pressure overload (stenosis) versus volume overload (regurgitation), and their anatomical location (aortic versus mitral). +--------------------------------------------------------------------------------------------------------------------+

| MASTER VALVULAR HEMODYNAMIC MANAGEMENT MATRIX |

+-----------------------+---------------------+-------------------+---------------------+----------------------------+

| Valvular Lesion | Primary Remodeling | Heart Rate Goal | Preload Goal | Afterload (SVR) Goal |

+-----------------------+---------------------+-------------------+---------------------+----------------------------+

  • | **Aortic Stenosis** | Concentric LVH | **Slow-Normal** | **High / Full** | **Maintained / High** |
  • | (AS) | (Pressure Overload) | (60 - 70 bpm) | (Fills stiff LV) | (Preserves DBP and CPP) |

+-----------------------+---------------------+-------------------+---------------------+----------------------------+

  • | **Aortic Regurg** | Eccentric LVH | **Fast** | **Full** | **Low / Decreased** |
  • | (AR) | (Volume Overload) | (80 - 100 bpm) | (Maintains forward) | (Reduces regurg fraction) |

+-----------------------+---------------------+-------------------+---------------------+----------------------------+

  • | **Mitral Stenosis** | LA Dilation & RVH | **Slow** | **Normal / Full** | **Maintained** |
  • | (MS) | (LA Pressure ↑) | (60 - 70 bpm) | (Fills LV in diast) | (Avoid PVR triggers!) |

+-----------------------+---------------------+-------------------+---------------------+----------------------------+

  • | **Mitral Regurg** | Eccentric LVH & LA | **Fast** | **Full** | **Low / Decreased** |
  • | (MR) | (Volume Overload) | (80 - 100 bpm) | (Maintains forward) | (Promotes aortic ejection) |

+-----------------------+---------------------+-------------------+---------------------+----------------------------+

Aortic Stenosis (AS)

Anatomy & Severity: Normal aortic valve area (AVA) is 3.0 − 4.0 cm 2 3.0 - 4.0 \text{ cm}^2 3.0 − 4.0 cm 2 . Severe AS is defined as AVA < 1.0 cm 2 \text{AVA} < 1.0 \text{ cm}^2 AVA < 1.0 cm 2 (indexed AVA < 0.6 cm 2 / m 2 < 0.6 \text{ cm}^2/\text{m}^2 < 0.6 cm 2 / m 2 ), mean transvalvular gradient > 40 mmHg > 40 \text{ mmHg} > 40 mmHg , or peak jet velocity > 4.0 m/s > 4.0 \text{ m/s} > 4.0 m/s .

Pathophysiology: Chronic pressure overload forces the left ventricle to generate transvalvular systolic pressures exceeding 200 − 250 mmHg 200 - 250 \text{ mmHg} 200 − 250 mmHg , inducing concentric left ventricular hypertrophy (LVH) (sarcomeres added in parallel, thickened wall, reduced LV compliance). High intracavitary pressure increases myocardial wall tension ( T = P × r 2 h T = \frac{P \times r}{2h} T = 2 h P × r ​ ) and dramatically elevates myocardial oxygen demand ( M V O 2 MVO_2 M V O 2 ​ ).

Diastolic Filling & Atrial Kick: The stiff, non-compliant LV is critically dependent on late diastolic active filling ("atrial kick"), which contributes up to 30 − 40 % 30 - 40\% 30 − 40% of stroke volume . Sudden loss of sinus rhythm (e.g., atrial fibrillation or junctional rhythm) causes instantaneous hemodynamic collapse.

Hemodynamic Rules:

Heart Rate (60-70 bpm): Tachycardia shortens diastole (the only time the subendocardium is perfused) and increases M V O 2 MVO_2 M V O 2 ​ . Severe bradycardia ( < 50 bpm <50 \text{ bpm} < 50 bpm ) cannot be compensated by an increase in stroke volume because stroke volume is fixed across the stenotic orifice.

Rhythm: Maintain normal sinus rhythm at all times. Cardiovert new-onset atrial fibrillation immediately.

Preload: High-normal. Hypovolemia causes severe underfilling of the stiff LV, resulting in precipitous hypotension.

Afterload (SVR): Maintain high-normal SVR. Vasodilation drops diastolic blood pressure (DBP), collapsing coronary perfusion pressure ( C P P = D B P − L V E D P CPP = DBP - LVEDP CPP = D BP − L V E D P ). Phenylephrine is the vasopressor of choice; avoid spinal or rapid epidural boluses.

Aortic Regurgitation (AR)

Pathophysiology: Incompetent aortic valve leaflets allow retrograde regurgitation of blood from the aorta into the LV during diastole. This creates chronic combined volume and pressure overload , resulting in eccentric LV hypertrophy (sarcomeres added in series, massive chamber dilation, "cor bovinum"). The stroke volume is split into forward stroke volume and backward regurgitant volume. Pulse pressure is markedly widened (e.g., 160 / 40 mmHg 160/40 \text{ mmHg} 160/40 mmHg ), with rapid arterial collapse (water-hammer / Corrigan pulse).

The Regurgitant Fraction Formula: Regurgitant Volume ∝ Regurgitant Orifice Area × Aortic-to-LV Diastolic Pressure Gradient × Diastolic Time \text{Regurgitant Volume} \propto \text{Regurgitant Orifice Area} \times \sqrt{\text{Aortic-to-LV Diastolic Pressure Gradient}} \times \text{Diastolic Time} Regurgitant Volume ∝ Regurgitant Orifice Area × Aortic-to-LV Diastolic Pressure Gradient ​ × Diastolic Time

Hemodynamic Rules ("Fast, Forward, Full"):

Heart Rate (80-100 bpm): Faster heart rates shorten diastole, directly decreasing the duration available for retrograde regurgitant flow.

Afterload (Decreased SVR): Vasodilation promotes forward aortic outflow into the systemic circulation and reduces retrograde flow back into the LV. Hydralazine, nitroprusside, or ACE inhibitors are beneficial.

Preload: Maintained/full to support augmented forward stroke volume.

Avoid: Bradycardia (prolonged diastole causes massive LV distension, elevated LVEDP, and acute pulmonary edema) and elevated afterload (forces blood back through the aortic valve).

Mitral Stenosis (MS)

Pathophysiology: Most commonly caused by rheumatic heart disease. Normal mitral valve area (MVA) is 4.0 − 5.0 cm 2 4.0 - 5.0 \text{ cm}^2 4.0 − 5.0 cm 2 . Severe MS occurs at MVA < 1.5 cm 2 \text{MVA} < 1.5 \text{ cm}^2 MVA < 1.5 cm 2 (critical MS < 1.0 cm 2 < 1.0 \text{ cm}^2 < 1.0 cm 2 ). Left ventricular inflow obstruction causes elevated left atrial pressure (LAP), progressive LA enlargement, and pulmonary venous congestion.

Secondary Pulmonary Hypertension & Cor Pulmonale: Chronic elevated LAP triggers reactive pulmonary arteriolar vasoconstriction, pulmonary arterial hypertension (PAH), right ventricular hypertrophy (RVH), tricuspid regurgitation, and right heart failure.

Hemodynamic Rules:

Heart Rate (60-70 bpm): Slow heart rate is vital. Diastolic filling across a stenotic mitral valve requires adequate time. Tachycardia drastically shortens diastolic filling, causing blood to back up into the pulmonary vasculature, precipitating acute flash pulmonary edema.

Rhythm: Maintain normal sinus rhythm. Loss of atrial kick combined with rapid ventricular response in atrial fibrillation is life-threatening.

Preload: Maintain normal intravascular volume. Overhydration causes acute pulmonary edema; dehydration severely starves the LV of preload.

Pulmonary Vascular Resistance (PVR): Strictly avoid triggers that increase PVR: hypoxemia ( P a O 2 < 60 PaO_2 < 60 P a O 2 ​ < 60 ), hypercapnia ( P a C O 2 > 45 PaCO_2 > 45 P a C O 2 ​ > 45 ), acidosis ( p H < 7.35 pH < 7.35 p H < 7.35 ), hypothermia, nitrous oxide ( N 2 O N_2O N 2 ​ O ), and sympathetic stimulation/pain .

Mitral Regurgitation (MR)

Pathophysiology: Incompetent mitral valve allows systolic ejection into both the high-resistance aorta and the low-pressure left atrium. This creates volume overload of both the left atrium and left ventricle, leading to eccentric LVH and LA enlargement. Severe MR is characterized by a prominent systolic v v v wave on pulmonary artery occlusion pressure (PAOP) tracings.

Hemodynamic Rules ("Fast, Forward, Full"):

Heart Rate (80-100 bpm): Slightly elevated heart rate shortens the systolic ejection period and prevents excessive ventricular dilation.

Afterload (Decreased SVR): Reducing systemic vascular resistance facilitates forward LV ejection into the aorta and minimizes backward regurgitation into the compliant left atrium.

Preload: High-normal to optimize forward stroke volume.

Avoid: Acute increases in SVR (e.g., pure alpha-1 agonists like phenylephrine increase regurgitant fraction and worsen pulmonary edema) and bradycardia.

2. Coronary Artery Disease & Myocardial Oxygen Balance +---------------------------------------------------------------------------------------------------------+

  • | MYOCARDIAL OXYGEN SUPPLY VS. DEMAND EQUILIBRIUM |
  • +----------------------------------------------------+----------------------------------------------------+
  • | Oxygen Supply Determinants | Oxygen Demand ($MVO_2$) Determinants |
  • +----------------------------------------------------+----------------------------------------------------+
  • | 1. **Coronary Perfusion Pressure (CPP):** | 1. **Heart Rate:** Most critical determinant! |
  • | • $CPP_{LV} = DBP - LVEDP$ | • Increases $MVO_2$ AND shortens diastolic supply|
  • | • Left Ventricle perfused in **diastole only** | 2. **Myocardial Wall Tension (Law of Laplace):** |
  • | • Right Ventricle perfused in **systole & diast**| • $\sigma = \frac{P \times r}{2h}$ |
  • | 2. **Diastolic Time Fraction:** | • Dependent on peak systolic pressure ($P$) and |
  • | • Shortened significantly by tachycardia | ventricular radius / preload ($r$) |
  • | 3. **Arterial Oxygen Content ($CaO_2$):** | 3. **Contractility ($dP/dt$):** |

| • $CaO_2 = (Hgb \times 1.34 \times SaO_2) + (0.003 \times PaO_2)$| • Inotropic stimulation increases $MVO_2$|

  • | 4. **Coronary Vascular Resistance:** | 4. **Basal Metabolic State:** |
  • | • Autoregulation (MAP 60-140 mmHg) & tone | • Hypothermia decreases; shivering increases |

+----------------------------------------------------+----------------------------------------------------+ C P P LV = Diastolic Blood Pressure (DBP) − Left Ventricular End-Diastolic Pressure (LVEDP) \mathbf{CPP_{\text{LV}} = \text{Diastolic Blood Pressure (DBP)} - \text{Left Ventricular End-Diastolic Pressure (LVEDP)}} CP P LV ​ = Diastolic Blood Pressure (DBP) − Left Ventricular End-Diastolic Pressure (LVEDP) C P P RV = Aortic Mean Arterial Pressure (MAP) − Right Ventricular End-Diastolic Pressure (RVEDP) \mathbf{CPP_{\text{RV}} = \text{Aortic Mean Arterial Pressure (MAP)} - \text{Right Ventricular End-Diastolic Pressure (RVEDP)}} CP P RV ​ = Aortic Mean Arterial Pressure (MAP) − Right Ventricular End-Diastolic Pressure (RVEDP)

NCE Clinical Rule — LV vs. RV Perfusion Dynamics:

The Left Ventricle is perfused almost exclusively during diastole because high intramyocardial tissue pressure during systole compresses intramural coronary vessels and halts subendocardial flow.

The Right Ventricle is perfused during both systole and diastole because RV systolic intracavitary pressure ( 25 mmHg 25 \text{ mmHg} 25 mmHg ) is significantly lower than aortic systolic pressure ( 120 mmHg 120 \text{ mmHg} 120 mmHg ). However, in severe pulmonary hypertension with RV peak pressure equaling systemic pressure, RV perfusion becomes diastole-dependent, rendering the RV exquisitely vulnerable to ischemia.

3. Cardiopulmonary Bypass (CPB): Circuit, Anticoagulation & Heparin Resistance [THE EXTRACORPOREAL CARDIOPULMONARY BYPASS CIRCUIT]

  • Right Atrium / Cavae ===================> Venous Reservoir
  • (Deoxygenated Blood) [Gravity / Vacuum] |
  • v
  • Cardiotomy Suction
  • (Surgical Field Blood)
  • |
  • v
  • Aortic Root / Ascending Aorta <=========== Main Arterial Pump
  • (Oxygenated Blood to Body) [Filter &] (Roller or Centrifugal)
  • [Heat Ex.] |
  • v
  • Membrane Oxygenator
  • (Gas Exchange: O₂ / CO₂)
  • Systemic Heparinization Protocol

Mechanism: Unfractionated heparin is a highly sulfated, negatively charged glycosaminoglycan (polyanion). It binds to Antithrombin III (ATIII) , inducing a conformational change that accelerates ATIII's inhibition of thrombin (Factor IIa), Factor Xa, IXa, XIa, and XIIa by 1 , 000 -fold 1,000\text{-fold} 1 , 000 -fold .

Dosing: Administer 300 − 400 units/kg 300 - 400 \text{ units/kg} 300 − 400 units/kg IV through a secure central line prior to aortic cannulation.

Target Activated Clotting Time (ACT):

Baseline ACT: ≈ 90 − 120 seconds \approx 90 - 120 \text{ seconds} ≈ 90 − 120 seconds .

Safe Cannulation ACT: > 300 seconds > 300 \text{ seconds} > 300 seconds .

Full Bypass ACT: > 400 − 480 seconds > 400 - 480 \text{ seconds} > 400 − 480 seconds (measured 3-5 minutes after heparin administration and every 30 minutes on bypass).

Heparin Resistance & Antithrombin III Deficiency

Definition: Failure to achieve an ACT > 400 − 480 seconds > 400 - 480 \text{ seconds} > 400 − 480 seconds despite administering a total heparin dose of 400 − 600 units/kg 400 - 600 \text{ units/kg} 400 − 600 units/kg .

Etiology:

Preoperative Heparin Therapy: Continuous IV heparin infusion in the ICU/CCU downregulates endogenous ATIII levels by 30 − 50 % 30 - 50\% 30 − 50% .

Congenital ATIII Deficiency: Rare autosomal dominant disorder.

Acquired ATIII Deficiency: Sepsis, hepatic cirrhosis (decreased hepatic synthesis), nephrotic syndrome (urinary protein loss), DIC, hemodialysis.

Treatment Protocol:

Administer an additional heparin bolus ( 100 − 200 units/kg 100 - 200 \text{ units/kg} 100 − 200 units/kg ).

If ACT remains < 400 seconds < 400 \text{ seconds} < 400 seconds , administer Antithrombin III Concentrate ( 500 − 1000 units 500 - 1000 \text{ units} 500 − 1000 units IV) or Fresh Frozen Plasma (FFP) ( 2 − 4 units 2 - 4 \text{ units} 2 − 4 units , each unit contains ≈ 200 − 250 units \approx 200 - 250 \text{ units} ≈ 200 − 250 units of endogenous ATIII).

4. Myocardial Protection: Cardioplegia Physiology +---------------------------------------------------------------------------------------------------------+

  • | CARDIOPLEGIA PHYSIOLOGIC CASCADE |
  • +---------------------------------------------------------------------------------------------------------+
  • | 1. **Hyperkalemic Composition:** Extracellular potassium elevated to **15 - 30 mEq/L** |
  • | 2. **Membrane Depolarization:** Resting membrane potential shifts from **-90 mV up to -50 mV** |
  • | 3. **Fast Na⁺ Channel Inactivation:** Voltage-gated fast Na⁺ channels locked in inactive state |
  • | 4. **Diastolic Arrest:** Phase 0 depolarization abolished → heart arrests in **flaccid diastole** |
  • | 5. **Metabolic Suppression:** Arrest eliminates mechanical work, reducing $MVO_2$ by **>90%** |
  • | 6. **Hypothermia (4°C):** Cold solution lowers myocardial temperature, reducing $MVO_2$ by **another 5%**|
  • +---------------------------------------------------------------------------------------------------------+

Antegrade vs. Retrograde Delivery:

Antegrade: Delivered into the aortic root (or directly into coronary ostia if aortic cross-clamp applied). Relies on a competent aortic valve to push solution down native coronary arteries. Ineffective in severe aortic regurgitation.

Retrograde: Delivered into the coronary sinus via an inflatable balloon catheter placed through the right atrium. Perfusion flows retrogradely from cardiac veins back through the capillary bed. Ideal in severe AR or severe multivessel coronary artery occlusion.

5. Weaning from Cardiopulmonary Bypass: The WARM Checklist +-------------------------------------------------------------------------+

  • | WEANING FROM CPB: THE "WARM" CHECKLIST |
  • +-------------------------------------------------------------------------+
  • | **W** - **Warmth:** Normothermia achieved |
  • | • Nasopharyngeal (core) temp: 36.5 - 37.0°C |
  • | • Bladder / Rectal temp: > 35.5°C (prevents afterdrop & coag) |
  • | |
  • | **A** - **Air Cleared & Anatomy:** |
  • | • TEE confirmation: Left ventricle, aortic root, & LA cleared |
  • | • Surgical vents turned off; cardiac chambers filled |
  • | |
  • | **R** - **Rhythm & Rate:** |
  • | • Stable sinus rhythm or AV-sequential epicardial pacing |
  • | • Target rate: 70 - 90 bpm (avoids bradycardia & tachycardia) |
  • | |
  • | **M** - **Monitoring, Metabolic, Mechanical & Medications:** |
  • | • **Mechanical Ventilation:** RESTARTED! 100% FiO₂, recruitment |
  • | • **Metabolic:** ABG normal, Hgb > 7.5-8 g/dL, K⁺ 4.0-5.0 mEq/L |
  • | • **Medications:** Inotropes/vasopressors infused as indicated |
  • +-------------------------------------------------------------------------+
  • 6. Protamine Sulfate Reversal & Adverse Reaction Subtypes

Protamine is a strongly basic, polycationic peptide purified from salmon sperm. When administered, positively charged protamine binds electrostatically to negatively charged heparin, forming an inert, stable salt precipitate without anticoagulant properties. D o s i n g : 1.0 − 1.3 mg Protamine Sulfate per 100 units of Heparin administered \mathbf{Dosing: \quad 1.0 - 1.3 \text{ mg Protamine Sulfate per } 100 \text{ units of Heparin administered}} Dosing : 1.0 − 1.3 mg Protamine Sulfate per 100 units of Heparin administered +---------------------------------------------------------------------------------------------------------+

  • | CLASSIFICATION OF PROTAMINE ADVERSE REACTIONS |
  • +-------------------+------------------------------------+------------------------------------------------+
  • | Reaction Type | Pathophysiologic Mechanism | Clinical Signs & Management |
  • +-------------------+------------------------------------+------------------------------------------------+
  • | **Type I** | • **Rapid Infusion (<10 mins)** | • Systemic vasodilation, drop in SVR and MAP |
  • | (Hypotension) | • Direct histamine & bradykinin rel| • **Rx:** Slow infusion over 10-15 minutes, |
  • | | from tissue mast cells | IV fluid bolus, phenylephrine |
  • +-------------------+------------------------------------+------------------------------------------------+
  • | **Type II** | • **True Allergic / Anaphylactic** | • Urticaria, facial flushing, severe broncho- |
  • | (Anaphylaxis / | • IgE or IgG anti-protamine antibod| spasm, catastrophic angioedema, shock |
  • | Anaphylactoid) | • **High Risk:** Prior NPH insulin,| • **Rx:** Epinephrine, diphenhydramine, |
  • | | fish allergy, post-vasectomy | steroids, fluid resuscitation |
  • +-------------------+------------------------------------+------------------------------------------------+
  • | **Type III** | • **Catastrophic Pulmonary HTN** | • Acute pulmonary vasoconstriction, massive |
  • | (Pulmonary | • Heparin-protamine complexes | rise in PAP and CVP, severe RV failure, |
  • | Vasoconstriction)| trigger complement activation & | acute tricuspid regurgitation, LV collapse |
  • | | **Thromboxane A2 release** | • **Rx:** Inhaled Nitric Oxide / Prostacyclin, |
  • | | | Milrinone, Vasopressin, re-institute CPB |
  • +-------------------+------------------------------------+------------------------------------------------+

NCE Exam Trap — Protamine Cross-Reactivity: Patients with a history of NPH (Neutral Protamine Hagedorn) insulin usage have been chronically exposed to protamine and can develop circulating anti-protamine antibodies. Similarly, patients who have undergone a vasectomy develop cross-reacting antisperm antibodies because the disrupted blood-testis barrier exposes protamine in sperm nuclei to the systemic immune system. Both patient populations carry a significantly elevated risk of life-threatening Type II anaphylaxis and Type III pulmonary vasoconstriction upon protamine exposure.

Loading diagram... Cardiopulmonary Bypass Hemodynamic Separation and Protamine Crisis Management